Sysmex and Matritech have dissolved a 2002 agreement under which Sysmex was granted a license for the use of Matritech's NMP 179 cervical cancer technology. Matritech, which is focused on point-of-care diagnostic tests, was recently acquired by Inverness Medical Innovations. Release